These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Inhibitory potency of 4- substituted sampangine derivatives toward Cu2+ mediated aggregation of amyloid β-peptide, oxidative stress, and inflammation in Alzheimer's disease.
    Author: Su C, Chen Y, Chen K, Li W, Tang H.
    Journal: Neurochem Int; 2020 Oct; 139():104794. PubMed ID: 32650027.
    Abstract:
    Cu2+ plays a key role in the pathogenesis of Alzheimer's disease (AD). The dysregulation of Cu2+ can cause neuronal damage and aggravate development of AD. Moreover, a series of 4-substituted sampangine derivatives have been investigated as inhibitors of acetylcholinesterase and β-amyloid (Aβ) aggregation for the treatment of AD in our previous studies. In the present study, we reported that one of these derivatives SD-1 was able to modulate Cu2+-mediated multiple pathological elements in AD. The high selectivity of SD-1 for Cu2+ over other biologically relevant metal ions was demonstrated by ITC. Western blotting analysis, light-scattering study, DCF-DA assay and paralysis experiment indicated that SD-1 suppressed the formation of Cu2+-Aβ species, alleviated the Cu2+-Aβ species induced neurotoxicity and inhibited the production of ROS catalyzed by Cu2+-Aβ species in SH-SY5Y cells over-expressing the Swedish mutant form of human APP (APPsw SH-SY5Y) and Aβ42 transgenic C elegans (CL2020). Furthermore, SD-1 inhibited the expressions of NO, iNOS, TNF-α, IL-1β and IL-6 induced by Cu2+ in BV2 microglial cells. Collectively, these findings provided valuable insights into the design and development of potent metal-chelating agents for AD treatment.
    [Abstract] [Full Text] [Related] [New Search]